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Objectives: Patients with ulcerative colitis reported that the complexity of the 
treatment regimen, the amount and frequency of administration of the therapy 
are key elements in influencing non-adherence to therapy. MethOds: The objec-
tive of this work was to evaluate the perception of patients with ulcerative coli-
tis compared to adherence to treatment, through a questionnaire distributed by 
clinicians of some Italian hospitals to patients with ulcerative colitis. Results: 
The survey involved 1,064 patients with an average age of 48 years, with a range 
between 5 and 90 years; 46% of the sample is female, 54% are males. More than 50% 
of patients surveyed has a disease duration of less than 10 years and about 35% last 
less than 5 years (median 8 years). There is a prevalence of cases of ulcerative left 
(51%). About 34% reported pancolitis, 14% proctitis and 0.5% chron. The 73% denied 
having adherence issues; the perception of adequate intake of therapy is almost 
complete: only 19% admit to not be adherent. The main reason for non-adherence 
to treatment, regardless of the formulation prescribed, remains forgetfulness (48%), 
followed by the fact of feeling good (20%). In this respect there is a significant differ-
ence depending on whether the disease is in the active phase (47%) or in remission 
(67%). cOnclusiOns: There is a strong adherence by patients, discordant from the 
literature. As regards the reasons for the non-adherence in the low percentage in our 
study, this result appears instead in line with what reported in literature. The direct 
consequence of a failure or suboptimal adherence to treatment involves more than 
the increase in the risk of recurrence of the disease, since patients often interrupt 
chronic medication because they feel good, even a simultaneous increase in costs 
borne by patients and health care system.
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Objectives: The EQ-5D is a standardized, non-disease-specific instrument for 
describing and valuing patients’ health-related quality of life (HRQoL). The aim 
of this study was to measure HRQoL with the use of the EQ-5D and to compare 
it with the self-evaluation of health state in patients with inflammatory bowel 
disease (IBD). MethOds: An online survey was performed. After having given 
informed consent and in order to gain experience with time trade-off (TTO) 
method, patients randomly chose two EQ-5D health states and assigned them 
appropriate utilities. Then, they were asked to assess their own health state by 
the means of EQ-5D, Visual analogue scale (VAS) and TTO. Results: 169 patients 
(76M, 93F) completed EQ-5D, VAS and TTO. Mean age of respondents was 29.9±8.98 
years (range: 18 to 61).73 patients suffered from ulcerative colitis (UC) and 84 from 
Cohn’s disease (CD). In 40 patients the diagnosis was made within one year, 91 
patients were 1-9 years and 38 at least 10 years since diagnosis. 43 patients had 
an operation because of IBD. Respectively, 30, 11, 67, 123 and 117 patients had at 
least moderate deterioration in domains: mobility, self-care, usual activities, pain/
discomfort and anxiety/depression. Mean EQ-5D value (using Polish TTO norms) 
was 0.829±0.162 and mean VAS score was 64.23±21.17. There was a significant 
correlation between EQ-5D and self-evaluation of health state (mean value 0.83, 
r= 0.279, p< 0.001). There was no statistically significant difference in any of the 
subgroup analyses in any of the subgroup analyses (CD vs. UC: 0.821 vs. 0.839, ≤ 1 
year vs. 1-9 years vs. ≥ 10 years from diagnosis: 0.827 vs. 0.815 vs. 0.866, operation 
vs. only conservative treatment: 0.823 vs. 0.831, p> 0.05). cOnclusiOns: EQ-5D 
appeared valid and informative in Polish IBD patients. However, it seems not to be 
sensitive enough to distinguish between different subgroups in this heterogeneous 
population.
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Objectives: In order to make decisions experts and patients have to face trade-
offs between benefit and harms. Harms can be expressed as the risk of occurrences 
and also the severity. Ideally a combination of both should be taken into account 
when making decisions. In the context of approval, allocation decisions and benefit 
assessment, the question arises as risk and severity of side-effects are included in 
the decision making process. MethOds: The discrete choice experiment used com-
pound side-effect attributes of a hepatitis C treatment by combining severity and 
risk. Thus, patients’ preferences regarding the probability of occurrence and severity 
of side-effects could be measured. The decision model included sustained-virologi-
cal-response, duration of therapy and number of interferon injections and five com-
pound side-effect attributes: rash, anemia, nausea/diarrhea, tiredness/fatigue and 
headache. The compound attribute were composed out of risk and severity, resulting 
in 6 levels per attribute. The experimental design (3*3+5*6) (Ngene) consisted of 
72choices, which were divided into 6 blocks. Results: N= 561 hepatitis C-patients 
(58.1%male) participated in computer-assisted personal interviews. Within the 
random parameter logit model (95%CI) the preference analysis could show that 
participants valued severity and risk of side-effects differently. The analysis of the 
six levels e.g. for the side-effect “anemia” was weighted the following: coef.“mild 
(NMA) has evaluated the relative efficacy of ciclosporin, prolonged-release (PR) 
and immediate-release (IR) tacrolimus in adult liver transplant recipients based on 
randomized controlled trials and large observational studies published since 2000. 
Based on the NMA findings, the present study evaluated the cost-utility of using 
PR tacrolimus relative to ciclosporin or IR tacrolimus in liver transplant recipi-
ents in the UK setting. MethOds: A Markov model was developed in Microsoft 
Excel to evaluate the cost-effectiveness of immunosuppressive regimens in liver 
transplant recipients. The model captured costs associated with immunosup-
pression, retransplantation and acute rejection (AR). Mortality, graft loss and 
AR odds ratios were derived from the NMA. Costs were taken from the British 
National Formulary and the NHS National Tariff and expressed in 2014 pounds 
sterling. Future costs and effects were discounted at 3.5% annually. Results: Over 
a 25-year time horizon, PR tacrolimus resulted in increased life expectancy and 
quality-adjusted life expectancy (QALE) relative to IR tacrolimus and ciclosporin. 
Relative to ciclosporin, QALE increased by 1.17 quality-adjusted life years (QALYs) 
with PR tacrolimus while costs increased by GBP 18,107, yielding an incremen-
tal cost-effectiveness ratio (ICER) of GBP 15,443 per QALY gained. Relative to IR 
tacrolimus, QALE increased by 0.78 QALYs and costs by GBP 1,646, resulting in an 
ICER of GBP 1,646 per QALY gained. Sensitivity analysis showed the analysis to be 
most sensitive to the dosing assumptions. cOnclusiOns: Based on a UK-specific 
analysis of the projected cost and effectiveness of PR tacrolimus relative to IR 
tacrolimus and ciclosporin, PR tacrolimus improved life expectancy and quality-
adjusted life expectancy relative to both IR tacrolimus and ciclosporin. While 
costs of PR tacrolimus were higher, the incremental cost-effectiveness ratios fell 
below GBP 20,000.
PGI38
EvALUATION Of ThE cOST EffEcTIvENESS AND SOcIETAL ImPAcT Of 
RIfAxImIN-Á 550mG IN ThE REDUcTION Of REcURRENcE Of OvERT hEPATIc 
ENcEPhALOPAThy IN ThE NEThERLANDS
Whitehouse JT1, Berni E2, Conway P3, Radwan A4, Henrar R5, Currie CJ6
1Norgine, Uxbridge, UK, 2Pharmatelligence, Cardiff, UK, 3Norgine Ltd, Harefield, UK, 4Norgine Ltd, 
Uxbridge, UK, 5Norgine B.V, Amsterdam, The Netherlands, 6Cardiff University, Cardiff, UK
Objectives: Hepatic encephalopathy (HE) is associated with high morbidity and 
mortality. Rifaximin-α 550mg is effective in reducing the recurrence of overt HE 
episodes, and hospital utilisation. We characterised the cost effectiveness includ-
ing societal impact of rifaximin-α 550mg plus a standard of care (SOC) versus SOC 
alone (lactulose) in patients with liver cirrhosis in The Netherlands. MethOds: A 
Markov state transition model was used. Outcome metrics were incremental cost 
effectiveness ratios (ICERs), derived from cost/quality adjusted life years (QALYs) 
estimates and estimates of impact of work productivity loss upon patient/carer 
using a friction cost method reflecting patient and societal considerations in the 
model. Outcomes data were from two trials of rifaximin-α 550mg. Dutch costs data 
(2010) were derived from published sources and societal cost estimates were from 
the Dutch costing manual (2010) inflated to 2015 prices. Health-related utility was 
estimated indirectly from disease-specific quality of life RCT data. The time horizon 
was five years. Costs and benefits were discounted at 4% and 1.5%, respectively. Real 
world data were applied into the model for length of hospital stay and number of 
admissions. Results: 5 year average costs of included care/societal elements was 
€ 88,386 in the rifaximin-α 550mg + SOC arm and € 82,968 in the SOC arm, a € 5,418 
difference. Corresponding values for benefits were 2.45 and 1.89 QALYs/person, 
respectively, a difference of 0.56 QALYs over five years. This translated into a cost 
effective base-case ICER of € 9,576 at a five year time horizon. cOnclusiOns: Use 
of rifaximin-α 550 mg + SOC in patients with recurrent HE in the context of liver 
cirrhosis represented good value and was cost-effective compared with SOC alone, 
by reducing overt HE episodes, the likelihood of hospital admission and hospital 
length of stay.
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Objectives: Hepatitis B infection is the major cause of chronic liver disease in 
Iran.This study has been designed to evaluate the cost-effectiveness of different 
options of medication therapy for CHB in Iran. MethOds: An economic evaluation 
of cost-utility was conducted to assess five oral medication strategies including: 
Adefovir, Lamivudine, Adefovir + Lamivudine, Entecavir, and Tenofovir. A Markov 
micro-simulation model was used to estimate the clinical and economic out-
comes in a life time horizon and based on a societal perspective. Medical and 
non-medical direct costs and indirect costs were included in the study and Life-
Years Gained (LYG) and Quality-Adjusted Life-Years (QALY) were determined as 
the measures of effectiveness. The results were presented in terms of Incremental 
Cost Effectiveness Ratio (ICER) per QALY or LYG. The model was consisted of nine 
states of the disease; the transition probabilities for the movement between the 
states were obtained using clinical evidences and expert opinions collected from 
all over the world. Probabilistic sensitivity analyses (PSA) was used to measure 
the effects of uncertainty in model parameters. Results: Results found that 
the Tenofovir treatment strategy was more effective and less costly than other 
options. In addition, Tenofovir had the highest QALY and LYG for the HBeAg -ve 
and HBeAg +ve with 13.52 and 15.21; 2133 and 21.53 (discounted) in all compari-
sons, respectively. Also, PSA proved the robustness of the model results. So that, 
The cost-effectiveness acceptability curves showed that TDF was the most cost-
effective treatment in 86.1% and 87.7% of the simulations for the HBeAg -ve and 
HBeAg +ve with WTP thresholds less than PPP $ 45270 (maximum WTP per QALY), 
respectively. cOnclusiOns: The results showed that using Tenofovir in patients 
with CHB was a highly cost-effective strategy.
